VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
VivoSim and Chemveda Life Sciences form collaboration to screen AI-designed drug compounds in human tissue models; first programs expected…
What this release says
VivoSim Labs and Chemveda Life Sciences announced a collaboration in which Chemveda designs and makes AI-derived drug compounds and VivoSim tests them in its human liver and intestine tissue models. The release says first programs are expected to begin in Q4 2026, so the offering has not yet produced results. For a shareholder, the deal is an announced partnership whose commercial impact is still unproven.
Key figures
- Compounds in clinical dataset
- 92 small-molecule compounds
- Liver model accuracy
- 91%
- Liver model sensitivity
- 90%
- Liver model specificity
- 95%
- Compounds screened in two weeks
- more than 20 compounds
- Toxicants detected by animal and traditional methods
- 50-65%
Positive for shareholders
- The collaboration gives VivoSim a named partner that can route AI-designed compounds to its testing models.
- The release says the FDA encourages human-relevant NAMs in place of animal testing, which the company says supports demand.
- The release cites a 92-compound dataset in which VivoSim's liver model predicted drug-induced liver injury with 91% accuracy.
Negative for shareholders
- First programs are only expected to begin in Q4 2026, so no revenue from the partnership is described yet.
- The performance figures come from the company's own data and are not independently verified in the release.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- NAM:
- New approach methodology, a non-animal testing method such as lab-grown human tissue models.
- CRDMO:
- Contract research, development and manufacturing organization, a firm that performs drug research and production for other companies for a fee.
- Sensitivity:
- The share of truly toxic compounds that a test correctly flags as toxic.
- Specificity:
- The share of safe compounds that a test correctly clears as safe.
FAQ
When will VivoSim and Chemveda start working together on programs?
The release says first programs are expected to begin in Q4 2026.
What does VivoSim do in the collaboration?
VivoSim evaluates selected compounds using its NAMkind Liver and NAMkind Intestine human tissue models, while Chemveda supports design, synthesis, optimization and development.
Who will the joint offering be available to?
The release says it will be available to Chemveda's global client base.
Historical context for VIVS
Across the 15 sessions after earlier VIVS headlines, the stock closed higher 5 times and lower 9 times, with a median move of 4.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VIVS | SPY |
|---|---|---|---|
| Oct 21, 2026 | VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling | +3.3% | +0.5% |
| Oct 7, 2026 | VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods | -5.2% | -0.2% |
| Sep 16, 2026 | VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs | -3.8% | -0.4% |
| Sep 1, 2026 | VivoSim Labs to Add Rat Liver Model to NAMkind Platform | -4.4% | -0.7% |
| Aug 6, 2026 | VivoSim Provides Financial and Listing Compliance Update | -9.2% | -0.2% |
| Jul 21, 2026 | VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services | -10.9% | +0.8% |
Keep researching VIVS
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Follow VIVS and get a push notification the moment its next story breaks.